Neuropsychiatric Symptoms in Patients With Alzheimer's Disease During SARS-COV-2 Pandemic in Peru.

IF 2.7 4区医学 Q2 CLINICAL NEUROLOGY

American Journal of Alzheimers Disease and Other Dementias Pub Date : 2021-01-01 DOI:10.1177/15333175211039089

Nilton Custodio, Sheila Castro-Suárez, Rosa Montesinos, Virgilio E Failoc-Rojas, Rossana Cruz Del Castillo, Eder Herrera-Perez

{"title":"Neuropsychiatric Symptoms in Patients With Alzheimer's Disease During SARS-COV-2 Pandemic in Peru.","authors":"Nilton Custodio, Sheila Castro-Suárez, Rosa Montesinos, Virgilio E Failoc-Rojas, Rossana Cruz Del Castillo, Eder Herrera-Perez","doi":"10.1177/15333175211039089","DOIUrl":null,"url":null,"abstract":"<p><p>To evaluate neuropsychiatric symptoms in patients with Alzheimer's disease (AD) and their association with cognition and functionality during lockdown of the COVID-19's first wave. We included 91 patients and caregivers of people with AD from a memory clinic. The RUDAS, M@T, and CDR were administered to patients and NPI/ADCS-ADL to caregivers. Baseline and lockdown measurements scales were analyzed to compare the frequencies at baseline versus lockdown and conditional Odds Ratio (ORc) was calculated for the neuropsychiatric symptoms. During the pandemic, significant increase in the number of cases was observed in depression (23%), agitation (36.8%), aberrant motor activity (12%), sleep disorders (26.3%), and appetite change (12.1%). In worsening of pre-existing symptoms, the most frequent were delusions (75%), followed by sleep disorders (71.7%). Lockdown induces a rapid increase of neuropsychiatric symptoms affecting cognitive symptoms and functionality of Peruvian patients with AD.</p>","PeriodicalId":50816,"journal":{"name":"American Journal of Alzheimers Disease and Other Dementias","volume":null,"pages":null},"PeriodicalIF":2.7000,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10581147/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"American Journal of Alzheimers Disease and Other Dementias","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1177/15333175211039089","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

To evaluate neuropsychiatric symptoms in patients with Alzheimer's disease (AD) and their association with cognition and functionality during lockdown of the COVID-19's first wave. We included 91 patients and caregivers of people with AD from a memory clinic. The RUDAS, M@T, and CDR were administered to patients and NPI/ADCS-ADL to caregivers. Baseline and lockdown measurements scales were analyzed to compare the frequencies at baseline versus lockdown and conditional Odds Ratio (ORc) was calculated for the neuropsychiatric symptoms. During the pandemic, significant increase in the number of cases was observed in depression (23%), agitation (36.8%), aberrant motor activity (12%), sleep disorders (26.3%), and appetite change (12.1%). In worsening of pre-existing symptoms, the most frequent were delusions (75%), followed by sleep disorders (71.7%). Lockdown induces a rapid increase of neuropsychiatric symptoms affecting cognitive symptoms and functionality of Peruvian patients with AD.

查看原文本刊更多论文

秘鲁 SARS-COV-2 大流行期间阿尔茨海默病患者的神经精神症状。

评估阿尔茨海默病患者（AD）的神经精神症状及其与 COVID-19 第一波封锁期间认知和功能的关联。我们纳入了一家记忆诊所的 91 名阿尔茨海默病患者及其护理人员。对患者进行了 RUDAS、M@T 和 CDR 测试，对护理人员进行了 NPI/ADCS-ADL 测试。通过分析基线和锁定测量量表，比较了基线和锁定时的频率，并计算了神经精神症状的条件比值比（ORc）。在大流行期间，抑郁（23%）、烦躁（36.8%）、异常运动（12%）、睡眠障碍（26.3%）和食欲改变（12.1%）的病例数明显增加。在原有症状恶化方面，最常见的是妄想（75%），其次是睡眠障碍（71.7%）。封锁导致神经精神症状迅速增加，影响了秘鲁注意力缺失症患者的认知症状和功能。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

American Journal of Alzheimers Disease and Other Dementias GERIATRICS & GERONTOLOGY-CLINICAL NEUROLOGY

CiteScore

5.40

自引率

0.00%

发文量

审稿时长

6-12 weeks

期刊介绍： American Journal of Alzheimer''s Disease and other Dementias® (AJADD) is for professionals on the frontlines of Alzheimer''s care, dementia, and clinical depression--especially physicians, nurses, psychiatrists, administrators, and other healthcare specialists who manage patients with dementias and their families. This journal is a member of the Committee on Publication Ethics (COPE).